This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Health Care Funds for a Healthy Portfolio

By William Ehart of InvestorPlace

The notion that health care stocks and mutual funds are recession resistant or defensive in nature has been lost in a thicket of worry about stocks in general as well as sector-specific fears about health care reform and patent expirations. Major pharmaceutical stocks with rock-solid financials are lagging on growth and regulatory concerns; biotechs offer growth and innovation but can't get a break as investors flee risk.

In today's market, investors would rather collect 2.95% on Johnson & Johnson (JNJ) 10-year bonds than 3.70% on its common shares.

But we don't need to look far afield for evidence health care stocks can offer shelter from the storm. The sector held up much better than the Standard & Poor's 500 Stock Index during the 2008 bear market, although it lagged in last year's rebound. The Biotech HOLDRS (BBH) actually gained 10% in 2008 versus the 37% decline of the S&P 500. But the shares rose just 11% last year compared with the nearly 27% gain of the market.

When all is said and done, the Biotech HOLDRS, the iShares Health Care Select Sector SPDR (XLV) and all the funds listed below have outperformed the S&P 500's 9% loss over the three years ended Thursday.

Meanwhile, valuations in the sector are at historical lows. According to data cited in the latest quarterly T. Rowe Price Report newsletter, health care valuations haven't been this low since a Clinton-era attempt at health care reform put fear into the markets in the early 1990s.

The data, compiled by Ned Davis Research using earnings estimates from Zacks Investment Research, show the price/earnings ratio of the S&P Health Care Sector is just 85% of that of the S&P 500 as a whole. Historically, the sector has traded at a premium to the index, and often a substantial one.

Concerns about the impact of President Barack Obama's health care reform, slower drug approvals, patent expirations and a lack of blockbuster new products from big pharmaceutical companies are very real. But the savvy portfolio managers behind some of the nation's best health care funds say the sector is due for a rebound given low valuations and even lower expectations. The likelihood health care reform will prove less onerous than expected also is real.

All of the following funds are rated four or five stars (out of five) by independent mutual fund rating firm Morningstar. All are no load, have expense ratios below 1.5% and have had the same portfolio managers for at least three years. Each is significantly less volatile than the overall market and held up substantially better than the S&P 500 during the bear market.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
XLV $64.01 0.77%
BBH $95.96 -4.90%
AAPL $95.01 0.00%
FB $99.54 -0.21%
GOOG $677.65 -0.75%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs